Pediatrics

Study results suggest young participants who survived cancer have difficulty in areas such as memory, attention, and ability to process information compared with those who did not have cancer.

The FDA prioritizes centanafadine's review for ADHD treatment, offering a novel, once-daily oral option for diverse patient needs.

New research reveals how specific gut bacteria in infants may reduce the risk of allergies and asthma, offering potential preventive strategies.

Jeffery Goad, PharmD, MPH, outlines how recent changes to the childhood immunization schedule may affect vaccine confidence, uptake, and public health, while highlighting the essential role pharmacists play in patient education.

Recent research reveals no significant link between prenatal acetaminophen use and increased risks of autism or ADHD in children, challenging FDA claims.

Nina Masters, PhD, MPH, explains how early adherence to pediatric vaccines strongly predicts timely measles-mumps-rubella (MMR) vaccination.

Food insecurity and social instability significantly increase long COVID risk in children, highlighting the need for targeted public health interventions.

According to the news release, the manufacturers have 30 days to respond.

Research reveals how eczema's timing and severity influence children's chances of outgrowing food allergies, highlighting the connection between skin health and allergy tolerance.

Subcutaneous copper histidinate injections deliver copper in a form that bypasses the genetic defect caused by Menkes disease.

Gestational diabetes disrupts RNA splicing in the placenta, revealing potential targets for improving pregnancy outcomes.

Morgan McSweeney, PhD, discusses why current US advisory structures are vulnerable to political influence, the vital role pharmacists play in sustaining vaccine confidence, and why universal hepatitis B vaccination remains essential in the US.

Federal vaccine recommendations for pediatric patients shift dramatically, reducing routine immunizations from 17 to 11, sparking debate on safety and efficacy.

Morgan McSweeney, PhD, discusses the evidence behind the hepatitis B vaccine’s safety, how pharmacists can communicate with concerned parents, and the impact of shifting federal guidance on vaccine confidence.

Research reveals that wildfire smoke exposure significantly impacts pediatric asthma control in the northeastern US, highlighting urgent climate health concerns.

Continuous glucose monitoring (CGM) significantly reduces the risk of high birth weight in babies born to mothers with gestational diabetes.

Medication errors are major public health issues, disproportionately affecting populations such as children, Ooder adults, and those with limited health literacy.

Six months following pneumococcal vaccination, over 70% of patients lost their protective titers, suggesting the need for more optimal vaccination strategies.

The FDA approves Accrufer for children 10 and older, offering a well-tolerated solution for iron deficiency, enhancing pediatric health outcomes.

Previously approved for patients 12 years and older, berotralstat now gives younger patients a treatment option to manage sudden hereditary angioedema attacks.

As the new chair of the Advisory Committee on Immunization Practices (ACIP) signals interest in revisiting childhood and adolescent vaccine schedules, immunologist Morgan McSweeney, PhD, stresses that any changes must be anchored in decades of rigorous safety and efficacy data.

New findings highlight the need for pneumococcal booster vaccinations in children with sickle cell disease to maintain immunity and prevent serious complications.

The FDA approved etuvetidigene autotemcel, the first gene therapy for Wiskott-Aldrich syndrome, transforming treatment options for affected patients.